Works matching IS 13479032 AND DT 2021 AND VI 112 AND IP 7


Results: 35
    1
    2
    3
    4

    Guidelines for clinical evaluation of anti‐cancer drugs.

    Published in:
    Cancer Science, 2021, v. 112, n. 7, p. 2563, doi. 10.1111/cas.14967
    By:
    • Minami, Hironobu;
    • Kiyota, Naomi;
    • Kimbara, Shiro;
    • Ando, Yuichi;
    • Shimokata, Tomoya;
    • Ohtsu, Atsushi;
    • Fuse, Nozomu;
    • Kuboki, Yasutoshi;
    • Shimizu, Toshio;
    • Yamamoto, Noboru;
    • Nishio, Kazuto;
    • Kawakami, Yutaka;
    • Nihira, Shin‐ichi;
    • Sase, Kazuhiro;
    • Nonaka, Takahiro;
    • Takahashi, Hideaki;
    • Komori, Yukiko;
    • Kiyohara, Koshin
    Publication type:
    Article
    5

    Correction.

    Published in:
    Cancer Science, 2021, v. 112, n. 7, p. 2931, doi. 10.1111/cas.15030
    Publication type:
    Article
    6

    Erratum.

    Published in:
    2021
    Publication type:
    Correction Notice
    7

    Correction.

    Published in:
    Cancer Science, 2021, v. 112, n. 7, p. 2930, doi. 10.1111/cas.15016
    Publication type:
    Article
    8
    9

    Correction.

    Published in:
    Cancer Science, 2021, v. 112, n. 7, p. 2928, doi. 10.1111/cas.15012
    Publication type:
    Article
    10
    11

    A stealth antigen SPESP1, which is epigenetically silenced in tumors, is a suitable target for cancer immunotherapy.

    Published in:
    Cancer Science, 2021, v. 112, n. 7, p. 2705, doi. 10.1111/cas.14973
    By:
    • Kosaka, Akemi;
    • Yajima, Yuki;
    • Hatayama, Mayumi;
    • Ikuta, Katsuya;
    • Sasaki, Takaaki;
    • Hirai, Noriko;
    • Yasuda, Syunsuke;
    • Nagata, Marino;
    • Hayashi, Ryusuke;
    • Harabuchi, Shohei;
    • Ohara, Kenzo;
    • Ohara, Mizuho;
    • Kumai, Takumi;
    • Ishibashi, Kei;
    • Hirata‐Nozaki, Yui;
    • Nagato, Toshihiro;
    • Oikawa, Kensuke;
    • Harabuchi, Yasuaki;
    • Celis, Esteban;
    • Okumura, Toshikatsu
    Publication type:
    Article
    12
    13

    A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B‐cell lymphoma.

    Published in:
    Cancer Science, 2021, v. 112, n. 7, p. 2845, doi. 10.1111/cas.14937
    By:
    • Terui, Yasuhito;
    • Rai, Shinya;
    • Izutsu, Koji;
    • Yamaguchi, Motoko;
    • Takizawa, Jun;
    • Kuroda, Junya;
    • Ishikawa, Takayuki;
    • Kato, Koji;
    • Suehiro, Youko;
    • Fukuhara, Noriko;
    • Ohmine, Ken;
    • Goto, Hideki;
    • Yamamoto, Kazuhito;
    • Kanemura, Nobuhiro;
    • Ueda, Yasunori;
    • Ishizawa, Kenichi;
    • Kumagai, Kyoya;
    • Kawasaki, Atsuko;
    • Saito, Tomohisa;
    • Hashizume, Misato
    Publication type:
    Article
    14
    15
    16
    17
    18
    19
    20
    21
    22

    CEBPγ facilitates lamellipodia formation and cancer cell migration through CERS6 upregulation.

    Published in:
    Cancer Science, 2021, v. 112, n. 7, p. 2770, doi. 10.1111/cas.14928
    By:
    • Shi, Hanxiao;
    • Niimi, Atsuko;
    • Takeuchi, Toshiyuki;
    • Shiogama, Kazuya;
    • Mizutani, Yasuyoshi;
    • Kajino, Taisuke;
    • Inada, Kenichi;
    • Hase, Tetsunari;
    • Hatta, Takahiro;
    • Shibata, Hirofumi;
    • Fukui, Takayuki;
    • Chen‐Yoshikawa, Toyofumi Fengshi;
    • Nagano, Kazuki;
    • Murate, Takashi;
    • Kawamoto, Yoshiyuki;
    • Tomida, Shuta;
    • Takahashi, Takashi;
    • Suzuki, Motoshi
    Publication type:
    Article
    23
    24

    CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.

    Published in:
    Cancer Science, 2021, v. 112, n. 7, p. 2915, doi. 10.1111/cas.14926
    By:
    • Taniguchi, Hiroya;
    • Nakamura, Yoshiaki;
    • Kotani, Daisuke;
    • Yukami, Hiroki;
    • Mishima, Saori;
    • Sawada, Kentaro;
    • Shirasu, Hiromichi;
    • Ebi, Hiromichi;
    • Yamanaka, Takeharu;
    • Aleshin, Alexey;
    • Billings, Paul R.;
    • Rabinowitz, Matthew;
    • Oki, Eiji;
    • Takemasa, Ichiro;
    • Kato, Takeshi;
    • Mori, Masaki;
    • Yoshino, Takayuki
    Publication type:
    Article
    25
    26
    27
    28
    29
    30
    31
    32
    33

    TET1 upregulation drives cancer cell growth through aberrant enhancer hydroxymethylation of HMGA2 in hepatocellular carcinoma.

    Published in:
    Cancer Science, 2021, v. 112, n. 7, p. 2855, doi. 10.1111/cas.14897
    By:
    • Shirai, Kiyokazu;
    • Nagae, Genta;
    • Seki, Motoaki;
    • Kudo, Yotaro;
    • Kamio, Asuka;
    • Hayashi, Akimasa;
    • Okabe, Atsushi;
    • Ota, Satoshi;
    • Tsutsumi, Shuichi;
    • Fujita, Takanori;
    • Yamamoto, Shogo;
    • Nakaki, Ryo;
    • Kanki, Yasuharu;
    • Osawa, Tsuyoshi;
    • Midorikawa, Yutaka;
    • Tateishi, Keisuke;
    • Ichinose, Masao;
    • Aburatani, Hiroyuki
    Publication type:
    Article
    34
    35

    Issue Information.

    Published in:
    Cancer Science, 2021, v. 112, n. 7, p. 2557, doi. 10.1111/cas.14472
    Publication type:
    Article